Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
63
ENSC Quote, Financials, Valuation and Earnings
Last price:
$7.98
Seasonality move
:
-16.27%
Day range:
$7.49 - $8.59
52-week range:
$2.12 - $30.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.52x
Volume:
154.8K
Avg. volume:
222.2K
1-year change:
-51.77%
Market cap:
$10.5M
Revenue:
--
EPS (TTM):
-$31.05
Analysts' Opinion
-
Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Ensysce Biosciences has an estimated upside of 1170.24% from its current price of $8.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $8.03.
Fair Value
-
According to the consensus of 0 analysts, Ensysce Biosciences has 1170.24% upside to fair value with a price target of -- per share.
ENSC vs. S&P 500
-
Over the past 5 trading days, Ensysce Biosciences has overperformed the S&P 500 by 45.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ensysce Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ensysce Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Ensysce Biosciences reported revenues of --.
Earnings Growth
-
Ensysce Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ensysce Biosciences reported earnings per share of $1.05.
Enterprise value:
6.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$20M | -$13.8M | -$6.3M | -$2.7M | $644.8K | |
| EBITDA | -$28.7M | -$12.5M | -$6.3M | -$2.7M | $665.8K | |
| Diluted EPS | -$3,610.95 | -$332.55 | -$31.05 | -$13.05 | $1.05 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $8.9M | $7.7M | $2.8M | $9.1M | |
| Total Assets | -- | $9.7M | $8.3M | $3.2M | $9.4M | |
| Current Liabilities | -- | $7M | $11.9M | $2M | $2.8M | |
| Total Liabilities | -- | $10.1M | $14.7M | $2.1M | $2.8M | |
| Total Equity | -- | -$385.3K | -$6.4M | $1.2M | $6.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.4M | -$12.3M | -$8.5M | -$2.3M | -$1M | |
| Cash From Investing | $4.5K | -- | -- | -- | -- | |
| Cash From Financing | $16M | $9.2M | $11.2M | -$102.5K | $4.1M | |
| Free Cash Flow | -$18.4M | -$12.3M | -$8.5M | -$2.3M | -$1M | |
ENSC
Sector
Market Cap
$10.5M
$43.9M
Price % of 52-Week High
25.99%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-51.77%
-29.11%
Beta (5-Year)
0.598
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$6.67
200-day SMA
Buy
Level
$7.64
Bollinger Bands (100)
Buy
Level
4.07 - 8.47
Chaikin Money Flow
Sell
Level
-163.4M
20-day SMA
Buy
Level
$7.22
Relative Strength Index (RSI14)
Buy
Level
53.82
ADX Line
Buy
Level
31.54
Williams %R
Neutral
Level
-22.7017
50-day SMA
Buy
Level
$7.25
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
632.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Stock Forecast FAQ
In the current month, ENSC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ENSC average analyst price target in the past 3 months is --.
-
Where Will Ensysce Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ensysce Biosciences share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Ensysce Biosciences?
Analysts are divided on their view about Ensysce Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ensysce Biosciences is a Sell and believe this share price will drop from its current level to --.
-
What Is Ensysce Biosciences's Price Target?
The price target for Ensysce Biosciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ENSC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ensysce Biosciences is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ENSC?
You can purchase shares of Ensysce Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ensysce Biosciences shares.
-
What Is The Ensysce Biosciences Share Price Today?
Ensysce Biosciences was last trading at $7.98 per share. This represents the most recent stock quote for Ensysce Biosciences. Yesterday, Ensysce Biosciences closed at $8.03 per share.
-
How To Buy Ensysce Biosciences Stock Online?
In order to purchase Ensysce Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 0.73% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.55% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
